Name of journal: World Journal of Diabetes
Manuscript NO: 92914
Title: MicroRNA-630: A promising avenue for alleviating inflammation in diabetic kidney disease
Provenance and peer review: Invited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 06301995
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer’s Country/Territory: China
Author’s Country/Territory: Spain
Manuscript submission date: 2024-02-10
Reviewer chosen by: AI Technique
Reviewer accepted review: 2024-02-11 01:38
Reviewer performed review: 2024-02-11 01:59
Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
<tr>
<td>Novelty of this manuscript</td>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade B: Good</td>
<td>[ ] Grade C: Fair</td>
</tr>
<tr>
<td></td>
<td>[ ] Grade D: No novelty</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creativity or innovation of this manuscript</td>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade B: Good</td>
<td>[ ] Grade C: Fair</td>
</tr>
<tr>
<td></td>
<td>[ ] Grade D: No creativity or innovation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
This paper discusses the feasibility of inhibition of TLR4 activation based on MicroRNA-630 in the treatment of DKD, which has clinical significance. However, there are several points in the paper that need to be revised or clarified. 1. Almost all studies on DKD anti-inflammatory therapy mentioned in the article have failed. This point I have a different view, because the current treatment of nephritis requires the use of glucocorticoids, glucocorticoids have a powerful anti-inflammatory effect. Perhaps the author wants to express a different meaning, the author can further clarify. 2. TLR4 is a key trigger factor for human innate immunity. Inhibiting the activation of TLR4 is an important blow to host innate immunity and will further induce other infections. Therefore, from this point, it can be seen that the therapeutic mechanism of MicroRNA-630 is not fundamentally different from the current glucocorticoid/immunosuppressive approach. I did not see from the paper that MicroRNA-630 is targeted and has no significant effect on the natural immunity of the host while treating DKD. It may also be that the author did not describe the effect of MicroRNA-630 on the natural immunity of the host, and I think this discussion should
not be missing.
Name of journal: World Journal of Diabetes

Manuscript NO: 92914

Title: MicroRNA-630: A promising avenue for alleviating inflammation in diabetic kidney disease

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05914645
Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer’s Country/Territory: Netherlands

Author’s Country/Territory: Spain

Manuscript submission date: 2024-02-10

Reviewer chosen by: AI Technique

Reviewer accepted review: 2024-02-14 13:02

Reviewer performed review: 2024-02-20 15:29

Review time: 6 Days and 2 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Novelty of this manuscript</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Good</th>
<th>[ ] Grade C: Fair</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: No novelty</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Creativity or innovation of this manuscript</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Good</th>
<th>[ ] Grade C: Fair</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: No creativity or innovation</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
This is an editorial of the ground breaking work which discusses the role of TLR and micrRNA in ammeliorating and halting the progression of diabetic kidney disease in a rat module. The author examines this and discusses the molecular mechanisms underlying the interaction of the TLR and diabetic kidney disease and also discuss how micrRNA may serve as a target for reducing the burden or progression and thereby improving the lifestyle of patients with diabetic kidney disease. A few comments: 1. Some words may be more appropriate and have been highlighted in the attached text. 2. the conclusion is rathere long the authors of this editorial may considere renaming the place the put conclusion as summary and let the conclusion start from the last paragraph only the remove the first two words- In summary
RE-REVIEW REPORT OF REVISED MANUSCRIPT

Name of journal: World Journal of Diabetes
Manuscript NO: 92914
Title: MicroRNA-630: A promising avenue for alleviating inflammation in diabetic kidney disease
Provenance and peer review: Invited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 06301995
Position: Peer Reviewer
Academic degree: MD
Professional title: Doctor
Reviewer’s Country/Territory: China
Author’s Country/Territory: Spain
Manuscript submission date: 2024-02-10
Reviewer chosen by: Li Li
Reviewer accepted review: 2024-04-02 01:13
Reviewer performed review: 2024-04-02 01:15
Review time: 1 Hour

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ Y] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language quality</td>
<td>[ Y] Grade A: Priority publishing</td>
<td>[ ] Grade B: Minor language polishing</td>
<td>[ ] Grade C: A great deal of language polishing</td>
<td>[ ] Grade D: Rejection</td>
<td></td>
</tr>
<tr>
<td>Conclusion</td>
<td>[ ] Accept (High priority)</td>
<td>[ Y] Accept (General priority)</td>
<td>[ ] Minor revision</td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
</tr>
<tr>
<td>Peer-reviewer</td>
<td>Peer-Review: [ Y] Anonymous</td>
<td>[ ] Onymous</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


SPECIFIC COMMENTS TO AUTHORS

The author has answered my questions and I suggest that the paper be published.